Jin-Zhou Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jin-Zhou Zhu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Chao-Hui Yu
Zhejiang University
4 shared publications- Jian-Fu Zhang
Xuzhou Med Univ, Dept Gastroenterol, Affiliated Hosp, 99 West Huai Hai Rd, Xuzhou 221002, Jiangsu, Peoples R China
4 shared publications Sheng-Ping Zhu
1] Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China [2] Department of Physiology, Xuzhou Medical College, Xuzhou 221002, China
4 shared publicationsSu-Juan Fei
Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
4 shared publicationsTing-Ting Li
1] Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China [2] Department of Physiology, Xuzhou Medical College, Xuzhou 221002, China
4 shared publicationsXiao Qiao
1] Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China [2] Department of Physiology, Xuzhou Medical College, Xuzhou 221002, China
4 shared publications
Latest Publications
- Open Access
- 1 April 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (2) , 535-543
Computer-aided diagnostic system with automated deep learning method based on the AutoGluon framework improved the diagnostic accuracy of early esophageal cancer
Background: There have been studies on the application of computer-aided diagnosis (CAD) in the endoscopic diagnosis of early esophageal cancer (EEC), but there is still a significant gap from clinical application. We developed an endoscopic CAD system for EEC based on the AutoGluon framework, aiming to explore the feasibility of automatic deep learning (DL) in clinical application. Methods: The endoscopic pictures of normal esophagus, esophagitis, and EEC were collected from The First Affiliated Hospital of Soochow University (September 2015 to December 2021) and the Norwegian HyperKvasir database. All images of non-cancerous esophageal lesions and EEC in this study were pathologically examined. There were three tasks: task A was normal vs. lesion classification under non-magnifying endoscopy (n=932 vs. 1,092); task B was non-cancer lesion vs. EEC classification under non-magnifying endoscopy (n=594 vs. 429); and task C was non-cancer lesion vs. EEC classification under magnifying endoscopy (n=505 vs. 824). In all classification tasks, we took 100 pictures as the verification set, and the rest comprised as the training set. The CAD system was established based on the AutoGluon framework. Diagnostic performance of the model was compared with that of endoscopists grouped according to years of experience (senior >15 years; junior Results: In tasks A and B, the accuracies of medium-performance CAD and high-performance CAD were lower than those of junior doctors and senior doctors. In task C, the medium-performance and high-performance CAD accuracies were close to those of junior doctors and senior doctors. The high-performance CAD model outperformed the junior doctors in both task A (0.850 vs. 0.830) and task C (0.840 vs. 0.830) in sensitivity comparison, but there was still a large gap between high-performance CAD models and doctors in sensitivity comparison. In task A, with the aid of CAD pre-interpretation, the accuracy of junior and senior physicians were significantly improved (from 0.880 to 0.915 and from 0.920 to 0.945, respectively); the time spent on film reading was significantly shortened (junior: from 11.3 to 8.7 s; senior: from 6.7 to 5.5 s). In task C, with the aid of CAD pre-interpretation, the accuracy of junior and senior physicians were significantly improved (from 0.850 to 0.865 and from 0.915 to 0.935, respectively); the reading time was significantly shortened (junior: from 9.5 to 7.7 s; senior: from 5.6 to 3.0 s). Conclusions: The CAD system based on the AutoGluon framework can assist doctors to improve the diagnostic accuracy and reading time of EEC under endoscopy. This study reveals that automatic DL methods are promising in clinical application.
- 1 April 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (2) , 535-543
Open AccessComputer-aided diagnostic system with automated deep learning method based on the AutoGluon framework improved the diagnostic accuracy of early esophageal cancer
Background: There have been studies on the application of computer-aided diagnosis (CAD) in the endoscopic diagnosis of early esophageal cancer (EEC), but there is still a significant gap from clinical application. We developed an endoscopic CAD system for EEC based on the AutoGluon framework, aiming to explore the feasibility of automatic deep learning (DL) in clinical application. Methods: The endoscopic pictures of normal esophagus, esophagitis, and EEC were collected from The First Affiliated Hospital of Soochow University (September 2015 to December 2021) and the Norwegian HyperKvasir database. All images of non-cancerous esophageal lesions and EEC in this study were pathologically examined. There were three tasks: task A was normal vs. lesion classification under non-magnifying endoscopy (n=932 vs. 1,092); task B was non-cancer lesion vs. EEC classification under non-magnifying endoscopy (n=594 vs. 429); and task C was non-cancer lesion vs. EEC classification under magnifying endoscopy (n=505 vs. 824). In all classification tasks, we took 100 pictures as the verification set, and the rest comprised as the training set. The CAD system was established based on the AutoGluon framework. Diagnostic performance of the model was compared with that of endoscopists grouped according to years of experience (senior >15 years; junior Results: In tasks A and B, the accuracies of medium-performance CAD and high-performance CAD were lower than those of junior doctors and senior doctors. In task C, the medium-performance and high-performance CAD accuracies were close to those of junior doctors and senior doctors. The high-performance CAD model outperformed the junior doctors in both task A (0.850 vs. 0.830) and task C (0.840 vs. 0.830) in sensitivity comparison, but there was still a large gap between high-performance CAD models and doctors in sensitivity comparison. In task A, with the aid of CAD pre-interpretation, the accuracy of junior and senior physicians were significantly improved (from 0.880 to 0.915 and from 0.920 to 0.945, respectively); the time spent on film reading was significantly shortened (junior: from 11.3 to 8.7 s; senior: from 6.7 to 5.5 s). In task C, with the aid of CAD pre-interpretation, the accuracy of junior and senior physicians were significantly improved (from 0.850 to 0.865 and from 0.915 to 0.935, respectively); the reading time was significantly shortened (junior: from 9.5 to 7.7 s; senior: from 5.6 to 3.0 s). Conclusions: The CAD system based on the AutoGluon framework can assist doctors to improve the diagnostic accuracy and reading time of EEC under endoscopy. This study reveals that automatic DL methods are promising in clinical application.
- 15 September 2020
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 129 (08) , 601-610
Liver Expressed Antimicrobial Peptide 2 is Associated with Steatosis in Mice and Humans
Background and Aims Liver expressed antimicrobial peptide 2 (LEAP2) is recently identified as a regulator in energy metabolism. This study aims to 1) investigate the role of leap2 in hepatic steatosis in C57BL/6 mice; 2) evaluate the association between circulating LEAP2 levels and liver fat contents in a hospital based case-control study. Methods The rodent experiment: western blotting and qPCR were performed to evaluate leap2 levels, lipid metabolism pathways and insulin signaling. shRNA was used to knockdown leap2. The clinical study: commercial ELISA kits were used to measure circulating LEAP2 levels (validated by western blotting). Liver fat content was estimated using MRI-derived proton density fat fraction and FibroScan-derived controlled attenuation parameter. Results The rodent experiment found the hepatic expression and secreted levels of leap2 were increased in mice with diet-induced steatosis. Leap2 knockdown ameliorated steatosis via lipolytic/lipogenic pathway and improved insulin sensitivity via IRS/AKT signaling. The clinical study reported increased circulating levels of LEAP2 in the subjects with steatosis. Moreover, LEAP2 correlated positively with age, body mass index, waist-to-hip ratio, liver fat content, fasting insulin and HOMA-IR, whereas inversely with acyl-ghrelin. Furthermore, the circulating levels of LEAP2 are dependent on liver fat content, acyl-ghrelin and fasting glucose. Lastly, circulating LEAP2 is an independent predictor of NAFLD. Conclusions The study suggests LEAP2 is associated with hepatic steatosis, which may involve lipolytic/lipogenic pathway and insulin signaling.
- 15 September 2020
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 129 (08) , 601-610
Liver Expressed Antimicrobial Peptide 2 is Associated with Steatosis in Mice and Humans
Background and Aims Liver expressed antimicrobial peptide 2 (LEAP2) is recently identified as a regulator in energy metabolism. This study aims to 1) investigate the role of leap2 in hepatic steatosis in C57BL/6 mice; 2) evaluate the association between circulating LEAP2 levels and liver fat contents in a hospital based case-control study. Methods The rodent experiment: western blotting and qPCR were performed to evaluate leap2 levels, lipid metabolism pathways and insulin signaling. shRNA was used to knockdown leap2. The clinical study: commercial ELISA kits were used to measure circulating LEAP2 levels (validated by western blotting). Liver fat content was estimated using MRI-derived proton density fat fraction and FibroScan-derived controlled attenuation parameter. Results The rodent experiment found the hepatic expression and secreted levels of leap2 were increased in mice with diet-induced steatosis. Leap2 knockdown ameliorated steatosis via lipolytic/lipogenic pathway and improved insulin sensitivity via IRS/AKT signaling. The clinical study reported increased circulating levels of LEAP2 in the subjects with steatosis. Moreover, LEAP2 correlated positively with age, body mass index, waist-to-hip ratio, liver fat content, fasting insulin and HOMA-IR, whereas inversely with acyl-ghrelin. Furthermore, the circulating levels of LEAP2 are dependent on liver fat content, acyl-ghrelin and fasting glucose. Lastly, circulating LEAP2 is an independent predictor of NAFLD. Conclusions The study suggests LEAP2 is associated with hepatic steatosis, which may involve lipolytic/lipogenic pathway and insulin signaling.
- Retracted
- 1 September 2020
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 246 (3) , Z1
RETRACTION: Leukocyte cell-derived chemotaxin 2 affects nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from steatosis, steatohepatitis, fibrosis and eventually cirrhosis. Leukocyte cell-derived chemotaxin 2 (LECT2), a new hepatokine, may be involved in energy metabolism. This study aims to 1) evaluate the association between LECT2 and NAFLD in multiple models; and 2) investigate the role of circulating LECT2 in the development of NAFLD in a multi-center cohort study. Western blotting, qPCR and ELISA were performed to evaluate hepatic and circulating LECT2 levels. siRNA, shRNA and AAV-plasmid were used to genetically modulate LECT2 expression. Multiple models included AML12 hepatocytes exposure to palmitic acid, high fat diet/ methionine-choline deficient diet-fed C57BL/6J female mice, mice injected with liver X receptor agonist/ tunicamycin/ various inflammatory mediators, and ob/ob mice. This study shows that hepatic LECT2 expression and circulating levels are elevated in multiple rodent NAFLD models and significantly induced in response to lipid deposition in the liver. Endoplasmic reticulum stress and inflammation also promote LECT2 expression and release. Gain-and loss-of-function studies reveal that LECT2 impacts NAFLD development and progression. Furthermore, a 6-year follow-up study of 1,278 subjects confirms the association between circulating LECT2 and the risk of NAFLD. Baseline LECT2 combines with Fatty liver index shows an performance (AUROC 0.735) to predict NAFLD development during the follow-up. In conclusion, LECT2 is expressed and released in response to NAFLD and liver injury. This study suggests the potential of LECT2 to be a biomarker for NAFLD.
- 1 September 2020
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 246 (3) , Z1
RetractedRETRACTION: Leukocyte cell-derived chemotaxin 2 affects nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from steatosis, steatohepatitis, fibrosis and eventually cirrhosis. Leukocyte cell-derived chemotaxin 2 (LECT2), a new hepatokine, may be involved in energy metabolism. This study aims to 1) evaluate the association between LECT2 and NAFLD in multiple models; and 2) investigate the role of circulating LECT2 in the development of NAFLD in a multi-center cohort study. Western blotting, qPCR and ELISA were performed to evaluate hepatic and circulating LECT2 levels. siRNA, shRNA and AAV-plasmid were used to genetically modulate LECT2 expression. Multiple models included AML12 hepatocytes exposure to palmitic acid, high fat diet/ methionine-choline deficient diet-fed C57BL/6J female mice, mice injected with liver X receptor agonist/ tunicamycin/ various inflammatory mediators, and ob/ob mice. This study shows that hepatic LECT2 expression and circulating levels are elevated in multiple rodent NAFLD models and significantly induced in response to lipid deposition in the liver. Endoplasmic reticulum stress and inflammation also promote LECT2 expression and release. Gain-and loss-of-function studies reveal that LECT2 impacts NAFLD development and progression. Furthermore, a 6-year follow-up study of 1,278 subjects confirms the association between circulating LECT2 and the risk of NAFLD. Baseline LECT2 combines with Fatty liver index shows an performance (AUROC 0.735) to predict NAFLD development during the follow-up. In conclusion, LECT2 is expressed and released in response to NAFLD and liver injury. This study suggests the potential of LECT2 to be a biomarker for NAFLD.
- 3 July 2020
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 28 (3) , 391-396
Serum netrin-1 as a biomarker for colorectal cancer detection
BACKGROUND: Recent evidence support that netrin-1 involves in colorectal carcinogenesis. OBJECTIVE: This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both clinical/screening sets. METHODS: A tota
- 3 July 2020
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 28 (3) , 391-396
Serum netrin-1 as a biomarker for colorectal cancer detection
BACKGROUND: Recent evidence support that netrin-1 involves in colorectal carcinogenesis. OBJECTIVE: This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both clinical/screening sets. METHODS: A tota
- 1 December 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 499, 134-141
Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease
- 1 December 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 499, 134-141
Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease
- Open Access
- 30 April 2019
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 17 (1) , 75
Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
The Toronto hepatocellular carcinoma (HCC) risk index (THRI) was developed to predict HCC in patients with cirrhosis. This study aimed to validate the THRI in a 10-year Asian cohort. A total of 2836 patients with cirrhosis at the First Affiliated Hospital of Soochow University between January 2008 and May 2018 were evaluated. Based on the THRI value at diagnosis, patients were divided into three groups (< 120, low-risk; 120–240, intermediate-risk; > 240, high-risk). Student’s t test and Fisher’s exact test were applied to compare parameters between the HCC group and the non-HCC group. The receiver operator characteristic (ROC) curve was drafted to identify the value of the THRI in predicting HCC. Logistic regression was utilized to assess the relationship between the development of HCC and THRI values. The incidence of HCC was calculated for the three groups using the Kaplan-Meier method, and curves were compared using the log-rank test. Of 520 patients enrolled in this study, 76 patients developed HCC. Patients who developed HCC had a higher THRI score than those who did not develop HCC (279.5 ± 57.1 vs. 232.3 ± 67.6, respectively, p < 0.001). The area under the ROC curve for the THRI to predict HCC was 0.707 ([95% CI 0.645–0.769], p < 0.001), with a sensitivity of 0.842 and a specificity of 0.486 when the cutoff THRI value was 226. Compared to the low-risk group, the high-risk group presented higher odds of developing HCC (adjusting odds ratio 1.026 [95% CI 1.002–1.051], p = 0.036). Differences existed in the cumulative incidence of HCC among the three risk groups (log-rank, p < 0.001). The 5-year cumulative HCC incidence of the low-risk group, intermediate-risk group, and high-risk group was 0%, 13%, and 34%, respectively. This study validated THRI values for predicting HCC in Asians with cirrhosis, which presented a fine sensitivity to identify the high-risk population of HCC for secondary prevention.
- 30 April 2019
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 17 (1) , 75
Open AccessValidation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
The Toronto hepatocellular carcinoma (HCC) risk index (THRI) was developed to predict HCC in patients with cirrhosis. This study aimed to validate the THRI in a 10-year Asian cohort. A total of 2836 patients with cirrhosis at the First Affiliated Hospital of Soochow University between January 2008 and May 2018 were evaluated. Based on the THRI value at diagnosis, patients were divided into three groups (< 120, low-risk; 120–240, intermediate-risk; > 240, high-risk). Student’s t test and Fisher’s exact test were applied to compare parameters between the HCC group and the non-HCC group. The receiver operator characteristic (ROC) curve was drafted to identify the value of the THRI in predicting HCC. Logistic regression was utilized to assess the relationship between the development of HCC and THRI values. The incidence of HCC was calculated for the three groups using the Kaplan-Meier method, and curves were compared using the log-rank test. Of 520 patients enrolled in this study, 76 patients developed HCC. Patients who developed HCC had a higher THRI score than those who did not develop HCC (279.5 ± 57.1 vs. 232.3 ± 67.6, respectively, p < 0.001). The area under the ROC curve for the THRI to predict HCC was 0.707 ([95% CI 0.645–0.769], p < 0.001), with a sensitivity of 0.842 and a specificity of 0.486 when the cutoff THRI value was 226. Compared to the low-risk group, the high-risk group presented higher odds of developing HCC (adjusting odds ratio 1.026 [95% CI 1.002–1.051], p = 0.036). Differences existed in the cumulative incidence of HCC among the three risk groups (log-rank, p < 0.001). The 5-year cumulative HCC incidence of the low-risk group, intermediate-risk group, and high-risk group was 0%, 13%, and 34%, respectively. This study validated THRI values for predicting HCC in Asians with cirrhosis, which presented a fine sensitivity to identify the high-risk population of HCC for secondary prevention.
- Open Access
- 1 December 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 359-364
Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
Background: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. Methods: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. Results: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all PP=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, PP=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). Conclusion: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy.
- 1 December 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 359-364
Open AccessSerum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
Background: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. Methods: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. Results: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all PP=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, PP=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). Conclusion: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy.
- 17 June 2015
- Published by Springer Nature in Cancer Causes & Control
- Vol. 26 (9) , 1245-1255
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis
We aim to investigate the association between angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) therapy and colorectal cancer (CRC) by conducting a systematic review with meta-analysis. Literature was searched on PubMed, Scopus, and the Cochrane library to identify relevant studies evaluating ACEIs/ARBs therapy and risk of CRC incidence or survival of CRC patients. Pooled risk ratio (RR) with 95 % confidence intervals was calculated for the association between ACEIs/ARBs and CRC risk and mortality. Eleven observational studies were included in the systematic review. A meta-analysis of six studies totaling 113,048 individuals indicated a 6 % decreased risk of CRC in ACEIs/ARBs users compared to non-users (95 % CI 0.89–0.98). In the four case–control studies, individuals using ACEIs/ARBs were associated with a 6 % decreased risk of CRC (95 % CI 0.90–0.99). The meta-analysis of three studies investigating the relationship between ACEIs/ARBs and survival of CRC did not show a significantly decreased mortality in ACEIs/ARBs users (RR 0.81, 95 % CI 0.60–1.09). Seven studies evaluated the dose–response relationship between ACEIs/ARBs therapy and CRC, and two of them showed that the association was related to longer duration and higher dose. CEIs/ARBs therapy might be associated with a reduce risk of CRC development, but whether use of these medications improves the outcomes of CRC remains unknown. Large-scale and more robust studies are needed to further explore this association.
- 17 June 2015
- Published by Springer Nature in Cancer Causes & Control
- Vol. 26 (9) , 1245-1255
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis
We aim to investigate the association between angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) therapy and colorectal cancer (CRC) by conducting a systematic review with meta-analysis. Literature was searched on PubMed, Scopus, and the Cochrane library to identify relevant studies evaluating ACEIs/ARBs therapy and risk of CRC incidence or survival of CRC patients. Pooled risk ratio (RR) with 95 % confidence intervals was calculated for the association between ACEIs/ARBs and CRC risk and mortality. Eleven observational studies were included in the systematic review. A meta-analysis of six studies totaling 113,048 individuals indicated a 6 % decreased risk of CRC in ACEIs/ARBs users compared to non-users (95 % CI 0.89–0.98). In the four case–control studies, individuals using ACEIs/ARBs were associated with a 6 % decreased risk of CRC (95 % CI 0.90–0.99). The meta-analysis of three studies investigating the relationship between ACEIs/ARBs and survival of CRC did not show a significantly decreased mortality in ACEIs/ARBs users (RR 0.81, 95 % CI 0.60–1.09). Seven studies evaluated the dose–response relationship between ACEIs/ARBs therapy and CRC, and two of them showed that the association was related to longer duration and higher dose. CEIs/ARBs therapy might be associated with a reduce risk of CRC development, but whether use of these medications improves the outcomes of CRC remains unknown. Large-scale and more robust studies are needed to further explore this association.
- 28 May 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (11) , 3194-3202
Prevalence of Nonalcoholic Fatty Liver Disease and Economy
Nonalcoholic fatty liver disease (NAFLD) is a growing health issue around the world. This study is to investigate whether adult prevalence of NAFLD correlates with national economic status. Literature search on PubMed database was conducted to identify eligible records fully published before September 2014. Gross national income (GNI) per capita was chosen to evaluate national economic status. Pearson coefficient, linear regression, and unpaired t test were performed in the statistical analyses. Twenty-one population-based surveys (seven in East Asia, five in South Asia, three in Middle East, and six in Europe) were included. The pooled prevalence of NAFLD was 24.24 %, and the global prevalence was positively correlated with GNI per capita (r = 0.4782, P = 0.0283). Europe witnessed a higher prevalence (28.04 %) than Middle East (12.95 %, P = 0.0092) and East Asia (19.24 %, P = 0.0083). Male presented a higher prevalence than female (P = 0.019), especially in Europe (P = 0.0132) and in Caucasians (P = 0.0383). Furthermore, male prevalence and rural prevalence individually were correlated with economic status (r = 0.5725, P = 0.0257 and r = 0.7389, P = 0.0060). Lastly, the urban (23.93 %) witnessed a higher prevalence than the rural or the urban + rural (12.65 %, P = 0.0141) in the countries of GNI per capita <$10,000. This study suggested that countries with higher economic status tend to present a higher prevalence of NAFLD. It is believed to provide a distinctive epidemiologic perspective to global situation of NAFLD.
- 28 May 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (11) , 3194-3202
Prevalence of Nonalcoholic Fatty Liver Disease and Economy
Nonalcoholic fatty liver disease (NAFLD) is a growing health issue around the world. This study is to investigate whether adult prevalence of NAFLD correlates with national economic status. Literature search on PubMed database was conducted to identify eligible records fully published before September 2014. Gross national income (GNI) per capita was chosen to evaluate national economic status. Pearson coefficient, linear regression, and unpaired t test were performed in the statistical analyses. Twenty-one population-based surveys (seven in East Asia, five in South Asia, three in Middle East, and six in Europe) were included. The pooled prevalence of NAFLD was 24.24 %, and the global prevalence was positively correlated with GNI per capita (r = 0.4782, P = 0.0283). Europe witnessed a higher prevalence (28.04 %) than Middle East (12.95 %, P = 0.0092) and East Asia (19.24 %, P = 0.0083). Male presented a higher prevalence than female (P = 0.019), especially in Europe (P = 0.0132) and in Caucasians (P = 0.0383). Furthermore, male prevalence and rural prevalence individually were correlated with economic status (r = 0.5725, P = 0.0257 and r = 0.7389, P = 0.0060). Lastly, the urban (23.93 %) witnessed a higher prevalence than the rural or the urban + rural (12.65 %, P = 0.0141) in the countries of GNI per capita <$10,000. This study suggested that countries with higher economic status tend to present a higher prevalence of NAFLD. It is believed to provide a distinctive epidemiologic perspective to global situation of NAFLD.
- 25 January 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (7) , 1889-1902
Systematic Review with Meta-Analysis: Alcohol Consumption and Risk of Colorectal Serrated Polyp
Alcohol intake is closely related to colorectal cancer, which remains inconsistent with studies on the relation between alcohol consumption and risk of colorectal serrated polyp (SP) which was proven to have potential of developing into malignant serrated neoplasm. A meta-analysis investigating the association between alcohol intake and colorectal SP with the dose–response of alcohol intake was conducted. The literature search was performed on PubMed to identify pertinent articles presenting results for at least three categories of alcohol consumption dated up to October 2014. Summarized relative risks (RRs) with 95 % confidence intervals (CIs) were estimated using random or fixed effects models based on statistical heterogeneity. A total of ten observational studies were identified in this meta-analysis. All drinkers were associated with 24 % increased risk of colorectal SP compared with non-/occasional drinkers. In particular, the light alcohol intake was not related to an increased risk of colorectal SP (RR 1.05, 95 % CI 0.93–1.18), whereas the RRs were 1.19 (95 % CI 1.02–1.40) for moderate alcohol intake and 1.60 (95 % CI 1.35–1.91) for heavy alcohol intake. The risks were consistent in further dose–response analysis. Meanwhile, subgroup analyses demonstrated that patients in America had more increased risk of SP with respect to those in Europe and Asia. In terms of subtype of colorectal SP, alcohol consumption had a greater influence on SSA than HP. This is the first meta-analysis that demonstrated the relationship between moderate and heavy alcohol consumption and increasing risks of colorectal SP.
- 25 January 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (7) , 1889-1902
Systematic Review with Meta-Analysis: Alcohol Consumption and Risk of Colorectal Serrated Polyp
Alcohol intake is closely related to colorectal cancer, which remains inconsistent with studies on the relation between alcohol consumption and risk of colorectal serrated polyp (SP) which was proven to have potential of developing into malignant serrated neoplasm. A meta-analysis investigating the association between alcohol intake and colorectal SP with the dose–response of alcohol intake was conducted. The literature search was performed on PubMed to identify pertinent articles presenting results for at least three categories of alcohol consumption dated up to October 2014. Summarized relative risks (RRs) with 95 % confidence intervals (CIs) were estimated using random or fixed effects models based on statistical heterogeneity. A total of ten observational studies were identified in this meta-analysis. All drinkers were associated with 24 % increased risk of colorectal SP compared with non-/occasional drinkers. In particular, the light alcohol intake was not related to an increased risk of colorectal SP (RR 1.05, 95 % CI 0.93–1.18), whereas the RRs were 1.19 (95 % CI 1.02–1.40) for moderate alcohol intake and 1.60 (95 % CI 1.35–1.91) for heavy alcohol intake. The risks were consistent in further dose–response analysis. Meanwhile, subgroup analyses demonstrated that patients in America had more increased risk of SP with respect to those in Europe and Asia. In terms of subtype of colorectal SP, alcohol consumption had a greater influence on SSA than HP. This is the first meta-analysis that demonstrated the relationship between moderate and heavy alcohol consumption and increasing risks of colorectal SP.